妊娠糖尿病中不良妊娠结果:系统性审查和元分析协议
Scholarstica Chukwuemeka1, Tawanda Chivese2, Aswathy Gopinath3
1School of Pharmacy, University of the Western Cape, Bellville, South Africa.
BMJ open
|May 28, 2024
概括
本系统性审查检查了妊娠糖尿病 (GDM) 的不同诊断标准如何影响报告的不良妊娠结果. 结果将比较全球不同地区的流行率和诊断方法.
科学领域:
- 产科和妇科 产科和妇科
- 内分泌学 在内分泌学.
- 公共卫生 公共卫生
背景情况:
- 孕期糖尿病 (GDM) 与母亲和胎儿的不良妊娠结果有关.
- 目前GDM的诊断标准在全球范围内有所不同,这导致对其对报告结果流行率的影响的不确定性.
- 需要清楚地了解不同的GDM诊断标准如何影响不良妊娠结果.
研究的目的:
- 系统地审查和比较患有GDM的女性不良妊娠结果的患病率,按不同的诊断标准分层.
- 描述和比较这些结果在世界各地的不同国家和地区.
- 为临床实践和公共卫生战略提供有关GDM诊断和管理的信息.
主要方法:
- 2010年至2021年间发表的观察性研究的系统审查和元分析.
- 在主要数据库 (PubMed,Scopus,CINAHL,Google Scholar) 进行全面的文献搜索和参考选.
- 使用偏差调整的逆方差异性和随机效应模型进行统计分析,根据地区,年龄,诊断标准和查方法进行子组分析.
主要成果:
- 不良妊娠结果的患病率估计将被组合起来,并以95%的置信区间报告.
- 将对不同GDM诊断方法的不良结果流行率进行比较.
- 小组分析将探讨根据地理区域,产妇年龄和GDM查方法的差异.
结论:
- 该研究将提供关于GDM诊断标准对不良妊娠结果的影响的关键数据.
- 调查结果将突出基于全球使用的诊断方法报告结果的潜在差异.
- 本系统性审查旨在指导GDM的标准化诊断方法,以改善孕产妇和胎儿健康结果.
相关概念视频
Pathophysiology of Diabetes
921
Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...
921
Diabetes Mellitus: Type 2 and Gestational
2.3K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.3K
Diabetes Mellitus: Overview and Type I Subtype
2.6K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.6K
Diabetes: Symptoms, Diagnosis, and Complications
524
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
524
Oral Hypoglycemic Agents: Biguanides and Glitazones
192
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Diabetes: Management and Pharmacotherapy
265
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
265


